Using advanced MRI techniques to differentiate between benign and malignant kidney masses

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to develop non-invasive imaging techniques to better understand the biology of renal masses, both benign and malignant. It utilizes advanced MRI methods, including Hyperpolarised MRI, Sodium MRI, and Deuterium metabolic imaging, to acquire detailed imaging data from human tissues. Participants will receive injections of hyperpolarised 13C pyruvate or consume deuterated glucose, allowing researchers to monitor metabolic changes in the kidney masses. The goal is to optimize imaging protocols to reduce unnecessary surgeries and biopsies for patients with renal masses.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Over 18 years old
* Able to and provide written informed consent to participate
* If female, postmenopausal or if women of child bearing potential (WOCBP) using a suitable contraception
* If male, using a suitable contraceptive method for the duration of the study
* Radiologically suspected or pathologically confirmed benign or malignant renal masses, as determined by standard clinical practice
* Capable of undergoing a minimum of one study visit

Exclusion Criteria:

* Contraindication or inability to tolerate MRI
* Pregnant or actively breast-feeding woman
* If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI safe at 3 T (researcher to confirm)
* Clinically significant cardiac, pulmonary or neurological diseases as determined by the investigators
* Laboratory abnormalities that may impact on the study results
* Any other significant medical or psychiatric history rendering the subject ineligible as deemed by the investigators

Where it's running

• University Department of Radiology
  Cambridge, Cambridgeshire, United Kingdom Recruiting

Study contacts

• Principal investigator: Ferdia A Gallagher, MD PhD — Principal Investigator
• Study coordinator: Ines Horvat-Menih, MD
• Email: ih357@cam.ac.uk
• Phone: +44 1223 767062

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Perioperative UDCA to Protect Kidney Function in Partial Nephrectomy

  This study tests whether giving ursodeoxycholic acid around surgery can help protect kidney function in adults having partial nephrectomy for kidney tumors.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07672860

• Side Effects and Resource Navigation Program for Cancer Patients

  This program tests whether a navigation service helps adults with kidney, bladder, breast, or lung cancer manage immunotherapy better than usual care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07646847

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• HC-7366 plus nivolumab with or without ipilimumab for advanced clear-cell kidney cancer (SHARK)

  This trial tests whether adding HC-7366 to nivolumab, with or without ipilimumab, can help control advanced clear-cell kidney cancer.

  Recruiting at 2 sites Phase 1 M.D. Anderson Cancer Center · Dallas, Texas and 1 other locations · NCT07401875

• Neoadjuvant HIF-2α inhibitor with or without PD-1 antibody for resectable clear cell kidney cancer

  This trial tests whether casdatifan alone or combined with zimberelimab can shrink tumors in people with resectable clear cell kidney cancer before surgery.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07397611

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.